mbiomics designs and develops microbiome-based therapeutics for the treatment of severe and chronic diseases. The company uses proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities, aiming to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and overcome disease.

mbiomics

We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.

HTGF | High-Tech Gruenderfonds

MIG Capital

Bayern Kapital

mbiomics GmbH

Thrilled to announce that mbiomics GmbH has been selected as a finalist to pitch at the BARDAVITAL Global Health Security Symposium on June 27 in Berlin - we are honored to be part of it.

Join our CEO Laura Figulla and watch her showcase our novel approach to microbiome-based therapeutics designed to access the full potential of the microbiome and to change the treatment paradigm in many chronic diseases.

This event focuses on visionary advancements in therapeutics innovation, and medical countermeasures aimed at enhancing pandemic preparedness and response for a safer future.

Register now ➡️ https://lnkd.in/dH4BWcKF

Be a part of the future of healthcare innovation — we hope to see you there!
#DigitalHealth #Vaccines #Therapeutics #GlobalHealth #Biotech @Biomedical Advanced Research and Development Authority (BARDA) @VITAL – A BARDA BAN Hub

This week, our CSO, Christopher Weidenmaier  and our CTO, Johannes B. Woehrstein provided their industry insights as part of European Pharmaceutical Review   #microbiome series. 

Chris and Jo highlighted the current challenges and opportunities in the development and manufacturing of next-generation live biotherapeutic products (#LBPs), which harbor a great therapeutic potential in a variety of indications, including #cancer.
Read the full article here https://bit.ly/4bwYOwd and learn more about our company’s proprietary #techbio platform that aims to combine the disease-modifying potential of large consortia with the safety and scalable manufacturability of GMP-manufactured non-engineered microbial strains at www.mbiomics.com

Our CEO and Co-founder, Laura Figulla, was recently featured in Drug Target Review's “Women in STEM” series, speaking about her experiences as a life science entrepreneur and what needs to be done to further support #GenderEquality in our sector. At mbiomics GmbH, a central goal in our corporate culture is to provide an inclusive work environment, and we are proud that these efforts are reflected by the fact that more than 50% of our R&D team members are women! 
🚀 🚀 🚀 🚀 

Read the full article here https://bit.ly/4a4sgsq and learn more about our company’s novel techbio approach to unlock the full potential of the #microbiome to overcome severe and chronic diseases at www.mbiomics.com

#WomenInSTEM

The #Microbiome just got some very neat coverage by the The Economist. 
As a long-term Econnmist reader, I was pretty excited about the microbiome therapeutics article published late 2023.
Having one of the best podcasts out there cover a topic I am super excited about is absolutely fantastic.

It’s exciting to see the innovation in the #microbiome field getting some well-deserved attention in last week's episode of The Economist's science & technology #podcast “Babbage”. Gilead Amit did a great job summarizing the challenges of current microbiome-based therapeutic interventions and discussing ways to tackle them.

We share the view that we need to move beyond the limitations of current state-of-the-art treatments and use the newest technologies to provide reliable and reproducible therapies for patients with severe and chronic indications. As part of this transformative field, we at mbiomics design and develop a novel class of complex live biotherapeutic products that recapitulate the functional diversity and activity of healthy microbiomes to overcome disease.
 
Listen to the full episode https://lnkd.in/ey2NeaSi and learn more about our novel #techbio platform approach at www.mbiomics.com.

mbiomics GmbH continues to grow in 2024!

Exciting Opportunity in Microbiome Therapeutics Development! We're seeking Bioinformatics and Computational Biology experts to drive cutting-edge drug discovery. 

Passionate about #microbiome #innovation? We're always open to applications from scientists eager to be at the forefront of this dynamic industry. Apply now and shape the future with us! 

#Biotech #Microbiome #Innovation #ScienceCareers #JoinOurTeam

https://lnkd.in/dARbtn_m

Today, we are welcoming Dr. Christopher Weidenmaier as our new Chief Scientific Officer. With nearly 20 years of experience in the field of microbiome and infectious disease, he will lead our discovery and development efforts as we build a pipeline of complex microbiome ecosystem product candidates. The strategic addition of Christopher to our leadership team will strengthen our ability to pursue our mission of harnessing the full potential of the microbiome to restore health and overcome disease. Great to have you on the team Chris!
 
Learn more about Chris and our mission here: https://bit.ly/3tHE04t

Metric
Company Name	mbiomics
Symbol
MSH ID	COM:MBIOMICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	DE
Stage
Employee Count	11
Website	mbiomics.com
LinkedIn	mbiomics-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MBIO

COM:MBIOMICS

mbiomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue